Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 33Thoracic 9Head & Neck 7Genitourinary 6Gynecologic 5Breast 5Dermatologic 4CNS 1

Conditions

Glioblastoma 40Brain Neoplasms 34Melanoma 15Glioma 13Carcinoma, Non-Small-Cell Lung 9Gliosarcoma 7Neoplasms 6Carcinoma, Renal Cell 6Stomach Neoplasms 5Ovarian Neoplasms 4Meningioma 4Lung Neoplasms 4Esophageal Neoplasms 4Colorectal Neoplasms 4Breast Neoplasms 4Astrocytoma 4Uterine Cervical Neoplasms 3Triple Negative Breast Neoplasms 3Sarcoma 3Recurrence 3Central Nervous System Neoplasms 3Uveal Melanoma 2Turcot syndrome 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Neuroblastoma 2Neoplasms, Germ Cell and Embryonal 2Neoplasm Metastasis 2

Interventions

regorafenib 2Nivolumab 2pembrolizumab 1aflibercept 1adavosertib 1Radiotherapy 1Radiation 1Paclitaxel 1NEO212 1Ipilimumab 1IFL protocol 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × pembrolizumab × CNS × Clear all
NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Neonc Technologies, Inc.

Phase 1/2 Recruiting
134 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡